MREO - Mereo BioPharma Group plc Stock Price and Quote

MREO [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-3.33	Insider Own	-	Shs Outstand	124.99M	Perf Week	-10.35%
Market Cap	88.35M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	124.99M	Perf Month	-21.99%
Income	-	PEG	-	EPS next Q	-	Inst Own	58.19%	Short Float / Ratio	3.06% / 4.44	Perf Quarter	26.66%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	3.83M	Perf Half Y	-19.67%
Book/sh	-0.22	P/B	-	EPS next Y	-	ROA	-	Target Price	4.25	Perf Year	-32.03%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.30 - 1.85	Perf YTD	-5.75%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-61.79%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	134.85%	ATR	0.09
Employees	49	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.03	Volatility	9.28% 10.85%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.04	Prev Close	0.71
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 28 AMC	Payout	0.00%	Avg Volume	862.40K	Price	0.71
Recom	1.50	SMA20	-13.85%	SMA50	-22.55%	SMA200	-29.37%	Volume	898,778	Change	-0.52%

Aug-12-22

Initiated

Cantor Fitzgerald

Overweight

May-05-21

Initiated

BTIG Research

Buy

$10

Apr-05-21

Initiated

Needham

Buy

$10

Mar-28-23 04:30PM	Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights GlobeNewswire
Mar-21-23 06:30AM	Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease GlobeNewswire +16.89%
Feb-08-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference GlobeNewswire
Jan-10-23 05:35AM	Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past year Simply Wall St. -7.12%
Nov-15-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks +5.92%
07:00AM	Loading…
Nov-08-22 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference GlobeNewswire
Nov-02-22 04:01PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency GlobeNewswire -6.97%
Oct-28-22 07:00AM	Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management GlobeNewswire
Oct-24-22 04:30PM	Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 GlobeNewswire
Oct-21-22 07:00AM	Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting GlobeNewswire
Oct-18-22 11:58AM	Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan Business Wire
07:00AM	Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value GlobeNewswire
Oct-17-22 07:00AM	Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease GlobeNewswire
Oct-03-22 05:00PM	Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders GlobeNewswire
09:00AM	Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five Business Wire
09:21AM	Loading…
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks Insider Monkey
Sep-26-22 07:00AM	Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board GlobeNewswire
Sep-14-22 09:00AM	Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders Business Wire
Sep-12-22 08:00AM	Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors GlobeNewswire
Sep-09-22 08:22PM	Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR GlobeNewswire +5.94%
Aug-31-22 07:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management GlobeNewswire
Aug-22-22 04:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management GlobeNewswire
Jul-05-22 04:01PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire
Jun-21-22 08:30AM	CEOs of NIO, NEXCF, MREO, and AIMLF Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Web 3.0, Wearables, Pharma, and Electric Vehicles. GlobeNewswire +30.00%
Jun-20-22 10:36AM	Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout Zacks
Jun-17-22 05:30PM	Mereo BioPharm and Theseus Pharmaceuticals See Action From Activist Investors Barrons.com +62.50%
03:53PM	AstraZeneca weighs bid for Mereo, Carnival Cruises partners with MGM, Devon Energy stock plunges Yahoo Finance Video
10:21AM	Why Mereo BioPharma Shares Are Jumping Today Benzinga
03:44AM	AstraZeneca weighing bid for Mereo BioPharma: report MarketWatch
Jun-02-22 08:00AM	Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan GlobeNewswire -5.12%
05:05PM	Loading…
May-26-22 05:05PM	Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting GlobeNewswire
04:30PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency GlobeNewswire
May-17-22 08:00AM	Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors GlobeNewswire
May-09-22 07:45AM	Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease Benzinga -31.30%
07:00AM	Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from ASTRAEUS Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema GlobeNewswire
May-06-22 05:12PM	Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat GlobeNewswire
05:12PM	Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat GlobeNewswire
Apr-22-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks
Apr-06-22 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-31-22 04:01PM	Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights GlobeNewswire +7.69%
Mar-03-22 08:30AM	Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022 GlobeNewswire
Mar-01-22 08:00AM	Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors GlobeNewswire
Feb-10-22 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -6.67%
Jan-12-22 01:59PM	Do Hedge Funds Love Mereo BioPharma Group plc (MREO)? Insider Monkey
Dec-29-21 01:19AM	UAB and Mereo BioPharma Group post positive results from Covid-19 clinical trial American City Business Journals
Dec-22-21 07:00AM	UAB and Mereo Announce Positive Top-line Results from COSTA a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease GlobeNewswire
Dec-17-21 12:38AM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com +7.55%
Dec-15-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com
Dec-13-21 07:00AM	Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereos Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting GlobeNewswire
Dec-10-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com
Nov-30-21 07:00AM	Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors GlobeNewswire
Nov-09-21 08:00AM	Mereo BioPharma to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-04-21 09:00AM	Data from Investigator-sponsored Trial of Mereo BioPharmas alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Oct-31-21 10:30AM	2 Growth Stocks That Could Deliver 1,000% Returns Motley Fool
Oct-26-21 10:26AM	Hedge Funds Are Crazy About Mereo BioPharma Group plc (MREO) Insider Monkey
08:00AM	Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency GlobeNewswire
Oct-13-21 08:00AM	Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment GlobeNewswire
Oct-01-21 04:31PM	Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting GlobeNewswire +7.02%
Sep-20-21 08:00AM	Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors GlobeNewswire -5.30%
Sep-09-21 08:00AM	Mereo BioPharma to Participate in Three Upcoming Investor Conferences GlobeNewswire
Aug-02-21 08:00AM	Mereo BioPharma to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference GlobeNewswire
Jul-19-21 07:04PM	Hedge Funds Are Crazy About Mereo BioPharma Group plc (MREO) Insider Monkey
Jun-02-21 09:45AM	Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome Benzinga
08:00AM	Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS) GlobeNewswire
May-27-21 08:00AM	Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference GlobeNewswire
May-04-21 08:00AM	Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021 GlobeNewswire
Apr-30-21 08:00AM	Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer GlobeNewswire
Apr-08-21 08:30AM	Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-31-21 05:02PM	Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights GlobeNewswire
Feb-25-21 11:33AM	Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks TipRanks
Feb-18-21 07:00AM	Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +9.02%
Feb-12-21 12:41PM	Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters Option to Purchase Additional American Depositary Shares GlobeNewswire -5.29%
Feb-10-21 07:00AM	Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire
Feb-09-21 04:03PM	Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Dec-21-20 10:26AM	Company News for Dec 21, 2020 Zacks
Dec-18-20 11:15AM	Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate Zacks +62.90%
07:45AM	The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga
Dec-17-20 04:05PM	Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta GlobeNewswire
04:05PM	Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta GlobeNewswire
Dec-15-20 01:00PM	Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital GlobeNewswire +8.46%
Dec-07-20 10:59PM	Is MREO A Good Stock To Buy Now? Insider Monkey
Nov-23-20 07:05AM	Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development GlobeNewswire
Nov-16-20 07:00AM	Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020 GlobeNewswire
Nov-10-20 07:23AM	Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference GlobeNewswire
Oct-20-20 07:00AM	Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs GlobeNewswire
Oct-19-20 07:00AM	Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT) GlobeNewswire +5.37%
Sep-29-20 07:00AM	Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update GlobeNewswire
Sep-24-20 07:00AM	Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta GlobeNewswire
Sep-16-20 08:00AM	Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020 GlobeNewswire
Sep-04-20 05:08AM	What Type Of Shareholders Own The Most Number of Mereo BioPharma Group plc (LON:MPH) Shares? Simply Wall St.
Aug-25-20 07:00AM	Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease GlobeNewswire
Aug-17-20 03:30PM	Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks TipRanks
Jun-30-20 07:00AM	Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development GlobeNewswire
Jun-16-20 07:00AM	Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019 GlobeNewswire
Jun-04-20 07:00AM	Mereo BioPharma Announces Completion of $70 Million Private Placement GlobeNewswire +55.61%
Mar-27-20 08:00AM	Business Update and Directorate Change GlobeNewswire -10.89%
Feb-28-20 07:00AM	Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta GlobeNewswire
Feb-19-20 07:21AM	The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA Benzinga +12.27%
03:00AM	Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor GlobeNewswire
Feb-12-20 08:00AM	Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab GlobeNewswire

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience